Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers Health (HIMS) Projected to Post Quarterly Earnings on Monday
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
SchaeffersResearch.com22h
Hims and Hers Stock Drops Weight as Earnings Loom
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Stock Soars on Momentum From Super Bowl Ad, RFK Confirmation
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...
HIMS Stock: Is The Risk Worth The Reward?
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...
Leerink sees potential for ‘reset’ in Hims & Hers with Ozempic shortage ended
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
Axios Vitals on MSN15h
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared ...